Cabbacis announced it will host an investor webinar on January 22 at 11:30 EST as part of its ongoing $7.5 million Regulation A offering. During the session, CEO and chairman Joseph Pandolfino will outline the company’s commercialization strategy for its patented iBlend cigarettes and vaporizer pods, which combine very-low-nicotine tobacco with non-intoxicating hemp and are positioned as harm-reduction products aimed at reducing nicotine dependence and supporting quit attempts.
The company will also update investors on its regulatory pathway with the U.S. Food and Drug Administration, leadership team, and plans for an international rollout later in 2026 to generate early revenue and brand validation ahead of U.S. market entry. Cabbacis said proceeds from the offering are intended to support product development and commercialization, positioning the company ahead of a potential FDA rule to cap nicotine levels in cigarettes, while expanding into reduced-nicotine and alternative tobacco formats.










